Morria Biopharmaceuticals Plc Announces Regulatory Approval To Commence Phase II Clinical Study Of MRX-4 In Allergic Rhinitis

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR). ...

All fields are Required.